FILTER BY PRODUCT
FILTER BY THERAPY AREA
Alexander Spira, et al. Preliminary Results from a Phase Ia/Ib, Open-label, Multicenter Study of ZL-1310, a DLL3-targeted ADC, to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer – NCT06179069
Shan Jing, et al. Pharmacokinetics, Pharmacodynamics, and Safety of Intravenous Efgartigimod and Subcutaneous Efgartigimod PH20 in Healthy Chinese Participants
Afshin Dowlati, et al. Abstract CT155: Trial in progress: A phase Ia/Ib, an open-label, multicenter study of ZL-1310 to evaluate the safety, tolerability, and pharmacokinetics in subjects with small cell lung cancer
Xiaohua Wu, et al. Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trial
Elena Garralda, et al. Abstract CT162: Trial in progress: A phase I, open-label, multicenter study of ZL-1218, an anti-CCR8 IgG1, as a single agent and as combination therapy with anti-PD-1 antibody to evaluate the safety, tolerability, and pharmacokinetics in subjects with advanced solid tumor
Jian Li, et al. Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China
Liu ZL, et al. Dose Modification for Chinese Patients on Niraparib Maintenance Treatment for Platinum-Sensitive Recurrent Ovarian Cancer: A Post Hoc Analysis. Presented as a poster presentation at the ESGO 2021 Congress, held virtually and in Prague, Czech Republic, October 23-25, 2021
Ai XH, et al. Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study. J Thorac Oncol. 2021 Aug; 16(8):1403-1414.
Howard JF, et al., Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021 Jul;20(7):526-536.
Wang J, et al. Safety Assessment of Niraparib Individualized Starting Dose in Patients with Platinum-Sensitive Recurrent Ovarian Cancer: A Randomized, Double-Blind, Placebo-Controlled, Phase III NORA Trial. Presented as a poster presentation at the ASCO Virtual 2021 Congress, held virtually, June 4-8, 2021
Wu LY, et al. Efficacy of Niraparib Maintenance Therapy in Chinese Women with Platinum-Sensitive Recurrent Ovarian Cancer with and Without Secondary Cytoreductive Surgery: Results from the NORA Trial. Presented as a poster presentation at the ASCO Virtual 2021 Congress, held virtually, June 4-8, 2021
Mok T, et al., KRYSTAL-12: A Randomized Phase 3 Study of Adagrasib (MRTX849) vs Docetaxel in Patients With Previously Treated Non–Small-Cell Lung Cancer (NSCLC) With KRASG12C Mutation, poster presentation at 2021 ASCO Annual Meeting.
Piotrowska Z, et al., Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20). Presentation at ASCO 2021 Virtual Congress
Wang B, et al. ZL-1201, A Differentiated CD47 Therapeutic Antibody with a Potentially Improved Hematological Safety Profile. Presented as a poster presentation at the AACR Virtual 2021 Congress, held virtually, April 10-15, 2021
Li J, et al. Population and Non-Compartmental Pharmacokinetic Analysis of Ripretinib and its Active Metabolite in Chinese Patients with Gastrointestinal Stromal Tumor. Presented as a poster presentation at the AACR Virtual 2021 Congress, held virtually, April 10-15, 2021
Wu XH, et al. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol. 2021 Apr; 32(4):512-521
Rugo HS, et al. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021;7(4):573-584. doi: 10.1001/jamaoncol.2020.7932.
Yang JX, et al. Efficacy and safety of niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer with complete or partial response to the last platinum-based chemotherapy: a subgroup analysis of the phase III NORA trial. Presented as a poster presentation at the SGO Virtual 2021 Congress, held virtually, March 19-21, 2021
Huang QD, et al. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer and a time-to-progression after penultimate platinum-based chemotherapy of 6-12 or ≥12 months: a subgroup analysis of the phase III NORA trial. Presented as a poster presentation at the SGO Virtual 2021 Congress, held virtually, March 19-21, 2021
Yin RT, et al. Evaluation of treatment response to niraparib in patients with platinum-sensitive recurrent ovarian cancer and measurable lesions at baseline: a sub-analysis of the phase III NORA trial. Presented as a poster presentation at the SGO Virtual 2021 Congress, held virtually, March 19-21, 2021
Wainberg ZA, et al., A double-blind randomized study of bemarituzumab (bema) plus mFOLFOX6 versus placebo plus mFOLFOX6 as first-line treatment for advanced gastric/gastroesophageal junction cancer (FIGHT), Journal of Clinical Oncology 2021; 39:3_suppl: 160-160.
Cho BC, et al., Phase 1/2 TRIDENT-1 Study of Repotrectinib in Patients with ROS1+ or NTRK+ Advanced Solid Tumors. Presentation at 2020 World Conference on Lung Cancer virtual congress.
Wang J, et al., A Phase 1, Open-Label Study of MGD013 (Tebotelimab), a Bispecific DART® Molecule Binding PD-1 and LAG-3, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma, presentation at 2020 ASH Annual Meeting
Bannerji R, et al., Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy, presentation at 2020 ASH Annual Meeting
Zhu JQ. Efficacy and Safety of Niraparib in Patients with Platinum-Sensitive Recurrent Ovarian Cancer (NORA) with Individualized Starting Dose. Efficacy and Safety of Niraparib in Patients with Platinum-Sensitive Recurrent Ovarian Cancer (NORA) with Individualized Starting Dose. Presented as an oral presentation at the ESMO Asia Virtual 2020 Congress, held virtually, November 20-22, 2020
Ai XH. A Randomized Double-blind Phase III Study of Niraparib versus Placebo as Maintenance Therapy in Extensive-stage Small Cell Lung Cancer. Presented as an oral presentation at the ESMO Asia Virtual 2020 Congress, held virtually, November 20-22, 2020
Patel, MR, et al., A Phase 1 Evaluation of Tebotelimab, a Bispecific PD-1 x LAG-3 DART® Molecule, in Combination with Margetuximab in Patients with Advanced HER2+ Neoplasms, poster presentation at 2020 SITC Annual Meeting
Hong DS. First-in-human safety, pharmacokinetics, and preliminary efficacy of TPX-0022, a novel inhibitor of MET/SRC/CSF1R in patients with advanced solid tumors harboring genetic alterations in MET (SHIELD-1). Presented at: 32nd EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium. October 24-25, 2020.
Zhu YS, et al. 尼拉帕利在肿瘤患者中的群体药代动力学分析. Presented as a poster at the CSCO 2020 Virtual congress, held virtually, China, September 19-26, 2020
抗PD-1/LAG-3 双亲和重定位 (DART®) 分子 Tebotelimab (MGD013) 单药治疗或与VEGFR/FGFR抑制剂布立尼布联合治疗在中国晚期肝癌 (HCC) 患者中的I期、开放性、剂量递增研究. Presentated as a oral presentation at the CSCO 2020 Congress, held virtually, China, September 19-26, 2020
Wu XH, et al. Individualized Starting Dose of Niraparib in Patients with Platinum Sensitive Recurrent Ovarian Cancer (NORA): A Randomized, Double Blind, Placebo Controlled, Phase III Trial. Presented as an oral presentation at the ESMO Virtual 2020 Congress, held virtually, September 19-21, 2020
Rao S, et al., POD1UM -202: Phase 2 Study of Retifanlimab in Patients With Squamous Carcinoma of the Anal Canal Who Progressed Following Platinum -Based Chemotherapy, presentation at ESMO 2020 Virtual Congress
Blay, J-V et al., Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumours (Invictus): A Double-Blind, Randomised, Placebo-Controlled, Phase 3 Trial, Lancet Oncol 2020; Volume 21, Issue 7: 932-934.
Luke fJ, et al., A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, a Bispecific DART® Molecule Binding PD-1 and LAG-3 in Patients with Unresectable or Metastatic Neoplasms, presentation at 2020 ASCO Virtual Scientific Program
Sagan O, et al., Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis, Antimicrobial Agents and Chemotherapy 2020; 64(3): 01506-19.
Gonzalez-Martin A, et al., Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer, N Engl J Med 2019; 381:2391-2402, DOI: 10.1056/NEJMoa1910962.
Giovanni L Ceresoli, et al. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. Lancet Oncol 2019 Dec;20(12):1702-1709.
O’Riordan W, et al., Once-daily Oral Omadacycline Versus Twice-Daily Oral Linezolid for Acute Bacterial Skin and Skin Structure Infections (OASIS-2): a Phase 3, Double-Blind, Multicentre, Randomised, Controlled, Non-Inferiority Trial, Lancet Infect Dis 201; 19: 1080–90. Published online August 29, 2019
Wu XH, et al. A Prospective Evaluation of Tolerability of Niraparib Dosing Based on Baseline Body Weight and Platelet Count: Blinded Pooled Interim Safety Data from the NORA Study. Presented as a poster presentation at the ESMO 2019 Congress, held in Barcelona, Spain, September 27-October 1, 2019
Moore KN, et al., Niraparib Monotherapy for Late-Line Treatment of Ovarian Cancer (QUADRA): a Multicentre, Open-Label, Single-Arm, Phase 2 Trial. Lancet Oncol 2019; 20: 636-48.
Zhang J, et al. A Phase I Study to Evaluate the Pharmacokinetics (PK) and Safety of Niraparib in Chinese Patients with Epithelial Ovarian Cancer (OC). Presented as a poster presentation at the AACR 2019, held in Atlanta, USA, March 29-April 3, 2019
Fredrick M Abrahamian, et al. Omadacycline for Acute Bacterial Skin and Skin-Structure Infections. N Engl J Med. 2019 Feb;380(6):528-538.
Stets R, et al., Omadacycline for Community-Acquired Bacterial Pneumonia, N Engl J Med 2019; 380:517-527, DOI: 10.1056/NEJMoa1800201
O’Riordan W, et al., Omadacycline for Acute Bacterial Skin and Skin-Structure Infections, N Engl J Med 2019; 380:528-538, DOI: 10.1056/NEJMoa1800170
Stupp R, et al., Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial, JAMA 2017;318(23):2306-2316. doi:10.1001/jama.2017.18718
Mirza MR, et al., Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med 2016; 375:2154-2164, DOI: 10.1056/NEJMoa1611310.
Stupp R, et al., NovoTTF-100: A versus physician’s choice chemotherapy in recurrent glioblastoma: A Randomised Phase III Trial of a Novel Treatment Modality, European Journal of Cancer 2012; 48: 2192-2202.